Tesaglitazar

SKU: orb1706553

Description

Tesaglitazar

Research Area

Metabolism Research, Molecular Biology

Key Properties

• CAS Number: 251565-85-2
• MW: 408.47
• Purity: 99.89% (May vary between batches)
• Formula: C₂₀H₂₄O₇S
• SMILES: CCO[C@@H](Cc1ccc(OCCc2ccc(OS(C)(=O)=O)cc2)cc1)C(O)=O
• Target: PPAR
• Solubility: DMSO:260 mg/mL (636.52 mM)

Bioactivity

• Target IC50:
  PPARα (rat):13.4 μM(EC50)|PPARα(human):3.6 μM(EC50)|PPARγ:0.2 μM(EC50)
• In Vivo:
  The aim of the present study was to determine whether tesaglitazar attenuates NAFLD and atherosclerosis development in diabetic low-density lipoprotein receptor-deficient (LDLr(-/-)) mice. Tesaglitazar therapeutic group (n=15, 20 μg/kg/day oral treatment for 6 weeks). Tesaglitazar decreased serum glucose and lipid levels compared with the diabetic mice and significantly reduced atherosclerotic lesions, lipid accumulation in the liver, macrophage infiltration, and decreased total hepatic cholesterol and triglyceride content compared to the diabetic mice. In addition, tesaglitazar reduced inflammatory markers at both the serum and mRNA levels. Tesaglitazar may be effective in preventing NAFLD and atherosclerosis in a pre-existing diabetic condition by regulating glucose and lipid metabolism, and the inflammatory response.
  Read more...

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

human PPARα, PPARβ, PPARγ, PPARα, rat PPARα, Tesaglitazar

Compound Identifiers

PubChem CID

208901